---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-030189"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:09:08.184587+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma reports FY2022 net loss of $9.4M; advances QRX003 trials for Netherton Syndrome

## Summary
- FY2022 net loss $9.4M; Q4 net loss $2.0M; cash & marketable securities $12.9M at year-end.
- Dosed first patient in double-blinded placebo-controlled study of QRX003 for Netherton Syndrome.
- Initiated second clinical trial of QRX003 in Netherton patients on off-label systemic therapy (FDA cleared).
- Completed public offering post-quarter with ~$6M net proceeds, extending cash runway into H2 2024.
- Working toward clinical testing in Australia for Scleroderma/Netherton programs in H2 2023.

## SEC filing metadata
- accession: 0001104659-23-030189
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/0001104659-23-030189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/tm238968d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-030189
- JSON: https://secwatch.observer/filing/0001104659-23-030189.json
- Plain text: https://secwatch.observer/filing/0001104659-23-030189.txt

## Key facts
- Earnings Releases
  Quoin Pharmaceuticals, Ltd. reported fourth quarter and full year of 2022 results: net income Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31.
  - Period: fourth quarter and full year of 2022
  - Net income: Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31
  - Result: reported results
  source text: Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31, 2022 was approximately $9.4 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/0001104659-23-030189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.